259 related articles for article (PubMed ID: 27379982)
1. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
4. GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma.
Ge L; Chen W; Cao W; Liu G; Zhang Q; Zhuang J; Zhang M; Yang J; Guo S; Zhao X; Guo H
Cancer Biomark; 2018; 22(3):395-403. PubMed ID: 29865032
[TBL] [Abstract][Full Text] [Related]
5. Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome.
Cornejo KM; Dong F; Zhou AG; Wu CL; Young RH; Braaten K; Sadow PM; Nielsen GP; Oliva E
Hum Pathol; 2015 Oct; 46(10):1411-7. PubMed ID: 26297250
[TBL] [Abstract][Full Text] [Related]
6. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma.
Yu ZH; Zhang Q; Wang YD; Chen J; Jiang ZM; Shi M; Guo X; Qin J; Cui GH; Cai ZM; Gui YT; Lai YQ
Asian Pac J Cancer Prev; 2013; 14(6):3729-34. PubMed ID: 23886173
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping.
Alomari AK; Nettey OS; Singh D; Kluger H; Adeniran AJ
Hum Pathol; 2015 Oct; 46(10):1418-26. PubMed ID: 26239624
[TBL] [Abstract][Full Text] [Related]
9. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
[TBL] [Abstract][Full Text] [Related]
10. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
[TBL] [Abstract][Full Text] [Related]
11. DNA ploidy pattern in papillary renal cell carcinoma. Correlation with clinicopathological parameters and survival.
del Vecchio MT; Lazzi S; Bruni A; Mangiavacchi P; Cevenini G; Luzi P
Pathol Res Pract; 1998; 194(5):325-33. PubMed ID: 9651945
[TBL] [Abstract][Full Text] [Related]
12. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
13. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
15. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma.
Stenman M; Laurell A; Lindskog M
Med Oncol; 2014 Mar; 31(3):841. PubMed ID: 24477648
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.
Tsimafeyeu I; Demidov L; Stepanova E; Wynn N; Ta H
Scand J Urol Nephrol; 2011 Apr; 45(3):190-5. PubMed ID: 21329481
[TBL] [Abstract][Full Text] [Related]
18. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.
Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J
Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888
[TBL] [Abstract][Full Text] [Related]
20. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]